Doctor of Science

NORD Welcomes Aliza Fink, D.Sc. as Director of Research Programs

Thursday, September 23, 2021 - 4:43pm

as the new Director of Research Programs.

Key Points: 
  • as the new Director of Research Programs.
  • "Research gives hope to rare disease patients and their families across the globe, and NORD is thrilled to have such a capable director to lead our research efforts," saidPeter L. Saltonstall, President and CEO of NORD.
  • In her role, Fink will lead the strategic development, growth, and implementation of NORD's research and scientific activities, ensuring that NORD drives innovation and advancement while supporting the rare community with evidence-informed programs.
  • Prior to joining NORD, Fink was most recently Senior Director of Real-World Research at Cystic Fibrosis Foundation and brings over 20 years of experience in research and epidemiology to leading NORD's research portfolio.

Autoliv's Research Advisory Board accelerates insights in automotive safety and new safety solutions for mobility and society

Wednesday, September 22, 2021 - 7:28am

STOCKHOLM, Sept. 22, 2021 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, strengthens its insights in automotive safety and the wider mobility safety arena, as Bryan Reimer and Hasse Johansson joins the Autoliv Research Advisory Board.

Key Points: 
  • STOCKHOLM, Sept. 22, 2021 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, strengthens its insights in automotive safety and the wider mobility safety arena, as Bryan Reimer and Hasse Johansson joins the Autoliv Research Advisory Board.
  • "We are very pleased to welcome Bryan Reimer and Hasse Johansson to the Autoliv Research Advisory Board.
  • Autoliv, the world's largest automotive safety supplier, is taking the position as the global leader in the wider mobility safety arena, beyond the light vehicle safety industry.
  • In the Autoliv Research Advisory Board, distinguished members exchange ideas, insights, and theories from their respective fields on an ongoing basis.

Autoliv's Research Advisory Board accelerates insights in automotive safety and new safety solutions for mobility and society

Wednesday, September 22, 2021 - 7:25am

STOCKHOLM, Sept. 22, 2021 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, strengthens its insights in automotive safety and the wider mobility safety arena, as Bryan Reimer and Hasse Johansson joins the Autoliv Research Advisory Board.

Key Points: 
  • STOCKHOLM, Sept. 22, 2021 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, strengthens its insights in automotive safety and the wider mobility safety arena, as Bryan Reimer and Hasse Johansson joins the Autoliv Research Advisory Board.
  • "We are very pleased to welcome Bryan Reimer and Hasse Johansson to the Autoliv Research Advisory Board.
  • Autoliv, the world's largest automotive safety supplier, is taking the position as the global leader in the wider mobility safety arena, beyond the light vehicle safety industry.
  • In the Autoliv Research Advisory Board, distinguished members exchange ideas, insights, and theories from their respective fields on an ongoing basis.

Study Designs Completed for NIH Consortium Study of Long-term COVID-19

Wednesday, September 15, 2021 - 4:41pm

As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.

Key Points: 
  • As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.
  • As of August 25, more than 39 million Americans had been infected with COVID-19, resulting in 648,000 deaths.
  • The study will also seek to enroll participants without SARS-CoV-2 infection to serve as a comparison group.
  • An important aspect of the RECOVER Initiative is the development of the pediatric main protocol for study of Long COVID in children.

SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th

Tuesday, September 14, 2021 - 1:30pm

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc .

Key Points: 
  • NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc .
  • h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference to be held virtually on Tuesday, September 28, 2021, at 4:00 p.m.
  • For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to Cantor at corporateaccess@cantor.com or KCSA Strategic Communications at SELLAS@kcsa.com .
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Tuesday, September 14, 2021 - 1:00pm

PH and HC are both rare forms of trigeminal autonomic cephalalgias (TAC), that are typically debilitating and difficult to treat.

Key Points: 
  • PH and HC are both rare forms of trigeminal autonomic cephalalgias (TAC), that are typically debilitating and difficult to treat.
  • gammaCore is also indicated for both the acute and preventative treatment of cluster headache, where it is considered a first-line treatment option.
  • The label expansion was based on data collected from multiple clinical audits and case series/case reports that included patients with PH or HC.
  • gammaCore (nVNS) is the first treatment, drug or device, to be indicated for the treatment of paroxysmal hemicrania or hemicrania continua, saidEric Liebler, Senior Vice President of Neurology at electroCore, Inc.

Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021

Thursday, September 9, 2021 - 12:00pm

The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021.

Key Points: 
  • The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021.
  • Thus far the blinded interim data we have seen on the primary and secondary endpoints of our RESCUE-ALS study are very encouraging.
  • We look forward to the unblinded topline readout before the end of the year.
  • Interim blinded efficacy results from the Phase 2 RESCUE-ALS study were presented at the ENCALS 2021 Annual Meeting on May 12, 2021.

ASHA Honors Nine Outlets and Two CSD Professionals with Media Award

Thursday, September 2, 2021 - 5:00am

The awardees include nine media outlets and two communication sciences and disorders professionals.

Key Points: 
  • The awardees include nine media outlets and two communication sciences and disorders professionals.
  • Annually, the awards recognize outstanding coverage by print, broadcast, and digital outlets and outreach by ASHA Certified Member audiologists and speech-language pathologists (SLPs).
  • "The essential work of communication professionals has taken on a new urgency during the pandemic," said ASHA 2021 President A. Lynn Williams, PhD, CCC-SLP.
  • ASHA's 2021 Media Award recipients are:
    The Washington Post: For "Some people think they have to lose their accent to get ahead.

Therapeutic Solutions International Announces Titan of Industry Dr. Peter Farrell Joins Advisory Board of its Suicide Prevention Spin-Off Campbell Neurosciences

Friday, August 20, 2021 - 2:00pm

ELK CITY, Idaho, Aug. 20, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that Peter C Farrell, PhD, DSc, AM joined the Advisory Board of its Spin-Off Company Campbell Neurosciences.

Key Points: 
  • ELK CITY, Idaho, Aug. 20, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that Peter C Farrell, PhD, DSc, AM joined the Advisory Board of its Spin-Off Company Campbell Neurosciences.
  • "It is with great honor that I welcome Dr. Farrell to the Campbell Neurosciences Advisory Board.
  • Dr. Farrell possesses the rare gift of being very business savvy while also being an acknowledged and well published scientist/engineer.
  • "We will support Campbell Neurosciences and Ms. O'Connor in whatever means necessary to achieve the goal of a world without suicide."

SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Thursday, August 12, 2021 - 9:22pm

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • (NASDAQ: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.
  • Financial Results for the Second Quarter 2021:
    Licensing revenue: Licensing revenue was $1.9 million for the second quarter of 2021 and $7.6 million for the first half of 2021 which consists of the recognition of revenue from the Companys license agreement with 3D Medicines.
  • R&D Expenses: Research and development expenses for the second quarter of 2021 were $3.5 million, as compared to $2.3 million for the same period in 2020.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.